Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop

Abstract

Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma characterized by the t(11;14) chromosomal translocation. This translocation most often results in overexpression of cyclin D1. MCL is clinically heterogeneous, outcomes are generally poor, and no standard treatment has been established. The recent approvals of ibrutinib and acalabrutinib have provided an additional therapeutic option; however, resistance has emerged as a significant issue and presents the need for more detailed studies of resistance mechanisms. Recent clinical trials have provided new perspectives on the relative efficacy and safety of various approaches for both transplant-eligible and transplant-ineligible patients. Multiple novel strategies are being evaluated in the treatment of MCL, including both targeted agents and cellular immunotherapies. At the Lymphoma Research Foundation’s 13th MCL Workshop, researchers gathered to discuss research findings, clinical trial results, and future directions related to MCL, its biology, and its treatment. This report, which includes a summary of each presentation, aims to review recent findings in MCL research and highlight potential areas for future study.

Keywords:

• Lymphoma and Hodgkin disease
• immunotherapy
• pharmacotherapeutics
• marrow and stem cell transplantation
• clinical results
• tumor microenvironment

Acknowledgements

This meeting, in addition to several projects presented, was supported by grants from the Lymphoma Research Foundation and the Foundation’s MCL Consortium. Each presenter whose work is included herein reviewed and approved the summary of that work. Additional meeting support was provided by the Foundation, AstraZeneca, and Celgene Corporation.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2019.1571205

Additional information

Funding

All coauthors are members of the LRF MCL Consortium Executive Committee; BSK, LIG, and ES are also members of the Foundation’s Scientific Advisory Board. BSK has received consulting funds from Genentech, Abbvie, Phamacyclics, and Acerta. PM has received consulting funds from Janssen, AstraZeneca, Gilead, Celgene, and Sandoz. MD has received institutional research support from Celgene, Janssen, Mundipharma, Roche, speakers honoraria from Bayer, Celgene, Gilead, Janssen, and Roche, and has served on advisory boards for Acerta, Bayer, Celgene, Gilead, Janssen, Novartis, Roche, and Sandoz. LIG has served on one-time advisory boards for Juno, Karyopharm, Gilead, and Celgene. LQ reports no additional conflicts of interest. EMS has received consulting funds from Pharmacyclics, Aztra Zeneca, KITE, Seattle Genetics, Celgene and Bayer.